Silence Therapeutics Plc risk profile
75 Stretched several inputs deteriorating together
Measured 21 October 2026 from SLN's filed statements. Recomputed nightly.
75 (Stretched), driven by Cash conversion at 100, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 42 | Elevated | Volatile | One-year price volatility — 150.7% |
| Operating pressure | 80 | Acute | Worsening | Costs outgrowing revenue — +83.4 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.00x |
| Leverage and coverage | 0 | Contained | Stable | Net debt to EBITDA |
| Competitive position | 80 | Acute | Stable | Operating-margin gap against peers — -16,293.4 percentage points |
| Concentration | 100 | Acute | Stable | Geographic concentration — 10,000 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Silence Therapeutics Plc